Skip to main content
SpringerLink
Log in

A Formulary Analysis of Angiotensin II Antagonists in a UK Teaching Hospital

  • Original Research Article
  • Published:
Disease Management & Health Outcomes

Abstract

Objective: To develop a method of value analysis which would facilitate an objective comparison of available angiotensin II antagonists as antihypertensive agents, in order to provide an adaptable framework which would allow for future developments in new product introduction and changes in evidence base.

Methods: Six angiotensin II antagonists were available for review at the time of the study: candesartan, eprosartan, irbesartan, losartan, telmisartan and valsartan. A team comprised of a cardiologist, a physician and a pharmacist conducted the evaluation. A nine-point selection criteria set was developed as a comparison framework. Each criterion was assigned a relative weighted value by the panel. Each drug product was systematically evaluated against each criterion to generate a series of product-criterion scores.

Results: A total score for each product was derived by combining product-criterion scores and the respective weighted values. The results obtained were presented to the hospital’s Drug and Therapeutics committee. Analysis of these scores ranked losartan highest (707), followed by valsartan (611) and candesartan (610). The agents most recently introduced on to the UK market scored the lowest.

Conclusion: The formulary analysis was accepted by the therapeutics committee as a viable method of comparison and consequently the previous formulary selections of candesartan and losartan was deemed to be justified.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V

Similar content being viewed by others

References

  1. Losartan, A new type of antihypertensive. MeReC Bull 1995; 6(6): 21–23.

    Google Scholar 

  2. Janknegt R, Steenhoek A. The System of Objectified Judgement Analysis (SOJA). A tool in rational drug selection for formulary inclusion. Drugs 1997; 53(4): 550–62.

    Article  PubMed  CAS  Google Scholar 

  3. Janknegt R, van Schaik BAM, Smits J, et al. ACE inhibitors and Angiotensin II antagonists for the treatment of hypertension: drug selection by means of the SOJA method. Eur Hosp Pharm 1997; 3(2): 46–58.

    Google Scholar 

  4. Janknegt R, de Leeuw PW, Dunselman PHJM, et al. Angiotensin II antagonists in hypertension: drug selection by means of the SOJA method. Eur Hosp Pharm 1999; 5 Suppl. 2: S53–63.

    Google Scholar 

  5. Santos-Ramos B, Pina-Vera MJ, Gragera EC, et al. Decision analysis applied to the selection of angiotensin-converting enzyme inhibitors. Pharm World Sci 1993; 15(5): 219–24.

    Article  PubMed  CAS  Google Scholar 

  6. Karr A. Improving the drug evaluation process. Pharm J 1994; 252: 576–7.

    Google Scholar 

  7. ABPI compendium of data sheets and summaries of product characteristics 1998–99. London: Datapharm Publications Limited, 2000.

  8. Solvay Healthcare Limited. Teveten (eprosartan mesylate). Summary of product characteristics. In: ABPI medicines compendium 2002. London: Datapharm Communications Limited, 2002: 1947–8.

    Google Scholar 

  9. Boehringer Ingelheim. Micardis (telmisartan). Summary of product characteristics. In: ABPI medicines compendium 2002. London: Datapharm Communications Limited, 2002: 1254–6.

    Google Scholar 

  10. Goa KL, Wagstaff AJ. Losartan potassium. A review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 1996; 51(5): 820–45.

    Article  PubMed  CAS  Google Scholar 

  11. Heuer HJ, Schondororfer G, Hogemann AM. Twenty-four hour blood pressure profile of different doses of candesartan cilexetil in patients with mild to moderate hypertension. J Hum Hypertens 1997; 11 Suppl. 2: S55–6.

    PubMed  CAS  Google Scholar 

  12. Oparil S, Dyke S, Harris F, et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 1996; 18(5): 797–810.

    Article  PubMed  CAS  Google Scholar 

  13. Fogari R, Ambrosoli S, Corradi L, et al. 24-hour blood pressure control by once daily administration of irbesartan assessed by ambulatory blood pressure monitoring. J Hypertens 1997; 15: 1511–8.

    Article  PubMed  CAS  Google Scholar 

  14. Hedner T, Himmelmann A, for the Eprosartan Multinational Study Group. The efficacy and tolerance of one and two daily doses of eprosartan in essential hypertension. J Hypertens 1999; 17(1): 129–36.

    Article  PubMed  CAS  Google Scholar 

  15. Neutel JM, Smith DHG. Dose response and antihypertensive efficacy of the ATI receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv Ther; 15 (4): 206–17.

  16. Hansten P, Horns J. Drug interactions analysis and management 2001. St. Louis (MO): Facts and Comparisons, 2001.

    Google Scholar 

  17. Stockley IM. Drug interactions. 5th ed. London: Pharmaceutical Press, 1999.

    Google Scholar 

  18. Hedner T, Oparil S, Rasmussen K, et al. Comparison of angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. Am J Hypertens 1999; 12: 414–7.

    Article  PubMed  CAS  Google Scholar 

  19. Andersson OK, Neldam S. A comparison of the antihypertensive effects of candesartan cilexetil and losartan in patients with mild to moderate hypertension. J Hum Hypertens 1997; 11 Suppl. 2: S63–4.

    PubMed  CAS  Google Scholar 

  20. Lacourciere Y, Asmar R, for the Candesartan/Losartan study investigators. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients. A placebo-controlled, forced titration study. Am J Hypertens 1999; 12: 1181–7.

    Article  PubMed  CAS  Google Scholar 

  21. Manolis AJ, Grossman E, Jelakovic B, et al., on behalf of the Losartan Trial Investigators. Effects of Losartan and Candesartan monotherapy and Losartan/Hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Clin Ther 2000; 22(10): 1186–203.

    Article  PubMed  CAS  Google Scholar 

  22. Kassler-Taub K, Littlejohn T, Elliot W, et al. Comparative efficacy of the two Angiotensin II receptor antagonists, irbesartan and losartan, in mild to moderate hypertension. Am J Hypertens 1998; 11(4 Pt 1): 445–53.

    Article  PubMed  CAS  Google Scholar 

  23. Oparil S, Guthrie R, Lewis AJ, et al. An elective titration study of the comparative effectiveness of two angiotensin II receptor blockers, irbesartan and losartan. Clin Ther 1998; 20: 398–409.

    Article  PubMed  CAS  Google Scholar 

  24. Mallion JM, Siche JP, Lacourciere Y, et al. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild to moderate hypertension. J Hum Hypertens 1999; 13: 657–64.

    Article  PubMed  CAS  Google Scholar 

  25. British national formulary 2001, no. 42. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2001: 95–6.

  26. Mitsunami K, Inoue S, Maeda K, et al. Three-month effects of candesartan cilexetil, an angiotensin II type 1 (ATI) receptor antagonist, on left ventricular mass and haemodynamics in patients with essential hypertension. Cardiovasc Drugs Ther 1998; 12(5): 469–74.

    Article  PubMed  CAS  Google Scholar 

  27. Tedesco MA, Ratti G, Aquino D, et al. Effects of losartan on hypertension and left ventricular mass: a long-term study. J Hum Hypertens 1998; 12(8): 505–10.

    Article  PubMed  CAS  Google Scholar 

  28. Almazov VA, Shlyakhto EV, Konrady AO, et al. Correction of hypertensive cardiac remodelling: comparison of different antihypertensive therapies. Med Sci Monit 2000;6(2):309–13.

    PubMed  CAS  Google Scholar 

  29. Omvik P, Gerdts E, Myking OL, et al. Long-term central haemodynamic effects at rest and during exercise of losartan in essential hypertension. Am Heart J 2000; 140(4): 624–30.

    Article  PubMed  CAS  Google Scholar 

  30. Nalbantgil S, Yilmaz H, Gurun C, et al. Effects of valsartan and enalapril on regresssion of left ventricular hypertrophy in patients with mild to moderate hypertension: a randomized, double blind study. Curr Therapeut Res Clin Experiment 2000; 61(6): 331–8.

    Article  CAS  Google Scholar 

  31. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321(7274): 1440–4.

    Article  PubMed  CAS  Google Scholar 

  32. Parving HH, Lehnert H, Brochner-Mortensen J, et al. Irbesartan in patients with type 2 diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. New Engl J Med 2001; 345(12): 870–8.

    Article  PubMed  CAS  Google Scholar 

  33. Fauvel JP, Velon S, Berra N, et al. Effects of losartan on renal function in patients with essential hypertension. J Cardiovasc Pharmacol 1996; 28(2): 259–63.

    Article  PubMed  CAS  Google Scholar 

  34. Nielsen S, Dollerup J, Nielsen B, et al. Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study. Neph Dial Trans 1997; 12 Suppl. 2: 19–23.

    Article  Google Scholar 

  35. Chan JC, Critchley JA, Tomlinson B, et al. Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly patients with or without non-insulin-dependent diabetes mellitus. Am J Nephrol 1997; 17(1): 72–80.

    Article  PubMed  CAS  Google Scholar 

  36. De Pablos Velasco PL, Martin FJM. Effects of losartan and diltiazem on blood pressure, insulin sensitivity, lipid profile and microalbuminuria in hypertensive type 2 diabetic patients. Clin Drug Invest 1998; 16(5): 361–70.

    Article  Google Scholar 

  37. Holdaas H, Hartmann A, Berg KJ, et al. Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy. Neph Dial Trans 1998; 13(12): 3096–102.

    Article  CAS  Google Scholar 

  38. Fernandez-Andrade C, Russo D, Iversen B, et al. Comparison of losartan and amlodipine in renally impaired hypertensive patients. Kidney Int Suppl. 1998; 68: S120–4.

    PubMed  CAS  Google Scholar 

  39. Lacourciere Y, Belanger A, Godin C, et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int 2000; 58(2): 762–9.

    Article  PubMed  CAS  Google Scholar 

  40. Buter H, Navis G, Dullaart RPF, et al. Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM. Neph Dial Trans 2001; 16(4): 771–5.

    Article  CAS  Google Scholar 

  41. Lozano JV, Llisterri JL, Aznar J, et al. Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. Neph Dial Trans 2001; 16 Suppl. 1: 85–9.

    Article  CAS  Google Scholar 

  42. Esmatjes E, Flores L, Inigo P, et al. Effect of losartan on TGF-(beta)l and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria. Neph Dial Trans 2001; 16 Suppl. 1: 90–3.

    Article  CAS  Google Scholar 

  43. Muirhead N, Feagen BF, Mahon J, et al. The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: a placebo-controlled trial. Curr Therapeut Res Clin Experiment 1999; 60(12): 650–60.

    Article  CAS  Google Scholar 

  44. Pitt B, Segal R, Martinez FA, et al., on behalf of ELITE Study Investigators. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747–52.

    Article  PubMed  CAS  Google Scholar 

  45. Pitt B, Poole-Wilson PA, Segal R, et al., on behalf of the ELITE II investigators. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial — the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582–87.

    Article  PubMed  CAS  Google Scholar 

  46. Franke H. Antihypertensive effects of candesartan cilexetil, enalapril and placebo. J Hum Hypertens 1997; 11 Suppl. 2: S61–2.

    PubMed  CAS  Google Scholar 

  47. Meineke I, Feltkamp H, Hogemann A, et al. Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate hypertension — a population analysis. Eur J Clin Pharmacol 1997; 53: 221–8.

    Article  PubMed  CAS  Google Scholar 

  48. Mclnnes GT, O’Kane KP, Jonker J, et al. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population. J Hum Hypertens 1997; 11 Suppl. 2:S75–80.

    Article  Google Scholar 

  49. Reif M, White WB, Fagan TC, et al. Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators. Am J Cardiol 1998; 82(8): 961–5.

    Article  PubMed  CAS  Google Scholar 

  50. Gradman AH, Gray J, Maggiacomo DO, et al., on behalf of the Eprosartan Study Group. Assessment of once-daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension. Clin Ther 1999; 21(3): 442–53.

    Article  PubMed  CAS  Google Scholar 

  51. Guthrie R, Saini R, Herman T, et al. Efficacy and tolerability of irbesartan, an angiotensin II receptor antagonist, in primary hypertension: a double-blind, placebo-controlled, dose titration study. Clin Drug Invest 1998; 15: 217–27.

    Article  CAS  Google Scholar 

  52. Pool JL, Guthrie RM, Littlejohn TW, et al. Dose-related antihypertensive effect of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens 1998; 11:462–70.

    Article  PubMed  CAS  Google Scholar 

  53. Mimran A, Ruilope L, Kerwin L, et al. A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension. J Hum Hypertens 1998; 12(3): 203–8.

    Article  PubMed  CAS  Google Scholar 

  54. Stumpe KO, Haworth D, Hoglund C, et al. Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension. Blood Press 1998; 7(1): 31–7.

    Article  PubMed  CAS  Google Scholar 

  55. Chan JC, Critchley JA, Lappe JT, et al. Randomized, double-blind, parallel study of the antihypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension. J Hum Hypertens 1995; 9(9): 765–71.

    PubMed  CAS  Google Scholar 

  56. Tikkanen I, Omvik P, Jensen H. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens 1995; 13(11): 1343–51.

    Article  PubMed  CAS  Google Scholar 

  57. Gradman AH, Arcuri KE, Goldberg AI, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995; 25(6): 1345–50.

    Article  PubMed  CAS  Google Scholar 

  58. Dahlöf B, Keller SE, Makris L, et al. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens 1995; 8(6): 578–83.

    Article  PubMed  Google Scholar 

  59. Byyny RL. Losartan potassium lowers blood pressure measured by ambulatory blood pressure monitoring. J Hypertens 1995; 13 Suppl. 1: S29–33.

    Article  CAS  Google Scholar 

  60. Townsend R, Haggert B, Liss C, et al. Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension. Clin Ther 1995; 17(5): 911–23.

    Article  PubMed  CAS  Google Scholar 

  61. MacKay JH, Arcuri KE, Goldberg AI, et al. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebocontrolled trial of concomitant administration compared with individual components. Arch Intern Med 1996; 156: 278–85.

    Article  PubMed  CAS  Google Scholar 

  62. Weir MR, Elkins M, Liss C, et al. Efficacy, tolerability and quality of life of losartan, alone or in combination with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension. Clin Ther 1996; 18(3): 411–28.

    Article  PubMed  CAS  Google Scholar 

  63. Oparil S, Barr E, Elkins M, et al. Efficacy, tolerability and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension. Clin Ther 1996; 18(4): 608–25.

    Article  PubMed  CAS  Google Scholar 

  64. Roca-Cusachs A, Oigman W, Lepe L, et al. A randomized, double-blind comparison of the antihypertensive efficacy and safety of once-daily losartan compared to twice-daily captopril in mild to moderate essential hypertension. Acta Cardiol 1997; 52(6): 495–506.

    PubMed  CAS  Google Scholar 

  65. Dahlof B, Lindholm LH, Carney S, et al. Main results of the losartan versus amlodipine (LOA) study on drug tolerability and psychological general wellbeing. J Hypertens 1997; 15: 1327–35.

    Article  PubMed  CAS  Google Scholar 

  66. Ikeda LS, Harm SC, Arcuri KE, et al. Comparative antihypertensive effects of losartan 50mg and losartan 50mg titrated to 100mg in patients with essential hypertension. Blood Press 1997; 6: 35–43.

    Article  PubMed  CAS  Google Scholar 

  67. Tiebel R, Vahlbruch A, Stapff M. Efficacy, safety, and effects on hypertensionassociated symptoms of losartan, alone or in combination with hydrochlorothiazide, versus amlodipine in patients with mild-to-moderate hypertension. Curr Therapeut Res Clin Experiment 1998; 59: 325–40.

    Article  CAS  Google Scholar 

  68. Wilson TW, Lacourciere Y, Barnes CC. The antihypertensive efficacy of losartan and amlodipine assessed with office and ambulatory blood pressure monitoring. Canadian Cozaar Hyzaar Amlodipine Trial Study Group. CMAJ 1998; 159(5): 469–76.

    PubMed  CAS  Google Scholar 

  69. Martina B, Weinbacher M, Drewe J, et al. Effects of losartan titrated to losartan/hydrochlorothiazide and amlodipine on blood pressure and peripheral capillary microcirculation in patients with mild-to-moderate hypertension. J Hum Hypertens 1998; 12: 473–8.

    Article  PubMed  CAS  Google Scholar 

  70. Conlin PR, Elkins M, Liss C, et al. A study of losartan, alone or with hydrochlorothiazide vs nifedipine GITS in elderly patients with diastolic hypertension. J Hum Hypertens 1998; 12: 693–9.

    Article  PubMed  CAS  Google Scholar 

  71. Owens P, Kelly L, Nallen R, et al. Comparison of antihypertensive and metabolic effects of losartan in combination with hydrochlorothiazide — a randomized controlled trial. J Hypertens 2000; 18: 339–45.

    Article  PubMed  CAS  Google Scholar 

  72. Karlberg BE, Lins LE, Hermansson K, et al. Efficacy and safety of telmisartan, a selective ATI receptor antagonist, compared with enalapril in elderly patients with primary hypertension. J Hypertens 1999; 17(2): 293–302.

    Article  PubMed  CAS  Google Scholar 

  73. Hegner G, Faust G, Freytag F, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficay and safety compared to hydrochlorothiazide. Eur J Clin Pharmacol 1997; 52(3): 173–7.

    Article  PubMed  CAS  Google Scholar 

  74. Mallion JM, Boutelant S, Chabaux P, et al. Valsartan, a new angiotensin II antagonist: efficacy and tolerability compared with an angiotensin-converting enzyme inhibitor enalapril in essential hypertension. Blood Press Monit 1997; 2(3–4): 179–84.

    PubMed  Google Scholar 

  75. Corea L, Cardoni O, Fogari R, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther 1996; 60(3): 341–6.

    Article  PubMed  CAS  Google Scholar 

  76. Holwerda NJ, Fogari R, Angeli P, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens 1996; 14(9): 1147–51.

    Article  PubMed  CAS  Google Scholar 

  77. Oparil S, Dyke S, Harris F, et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 1996; 18: 797–810.

    Article  PubMed  CAS  Google Scholar 

  78. Black HR, Graff A, Shute D, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Hum Hypertens 1997; 11(8): 483–9.

    Article  PubMed  CAS  Google Scholar 

  79. Benz JR, Black HR, Graff A, et al. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens 1998; 12:861–6.

    Article  PubMed  CAS  Google Scholar 

  80. Conlin PR, Spence JD, Williams B, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000; 13: 418–26.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

There were no sources of funding used to assist in conducting this study. Dr N. Wheeldon has sat on advisory boards for AstraZeneca and Novartis. He has received educational sponsorship from Bristol-Myers Squibb and Merck Sharp and Dohme.

Author information

Authors and Affiliations

  1. Department of Pharmacy, Northern General Hospital, Sheffield Teaching Hospitals Trust, Herries Road, Sheffield, S5 7AU, England

    Andrew P. Moore, Nigel M. Wheeldon (Professor) & Mike Jennings

  2. Department of Cariology, Northern General Hospital (Sheffield Teaching Hospital Trust), Sheffield, England

    Andrew P. Moore

  3. Department of Medicine, Northern General Hospital (Sheffield Teaching Hospital Trust), Sheffield, England

    Andrew P. Moore

Authors
  1. Andrew P. Moore
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nigel M. Wheeldon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mike Jennings
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew P. Moore.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moore, A.P., Wheeldon, N.M. & Jennings, M. A Formulary Analysis of Angiotensin II Antagonists in a UK Teaching Hospital. Dis-Manage-Health-Outcomes 10, 355–362 (2002). https://doi.org/10.2165/00115677-200210060-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00115677-200210060-00005

Keywords

Search

Navigation